

Atty. Dkt. No. EPI3003C
(068904-0204)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hiatt, et al.
Title: NOVEL EPITHELIAL TISSUE
IMAGING AGENT
Appl. No.: 10/062,467
Filing Date: February 5, 2002
Examiner:
Art Unit: 1651

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith a copy of the Form PTO-1449s (labeled Pages A, B, C, D and E) which were submitted to the U.S. PTO in parent application Serial No. 08/782,480, filed 01/10/1997, now U.S. Patent Number 6,045,774, Grant Date April 4, 2000. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application. Applicants request that the Examiner evaluate the documents from the parent case so that they may be made of record in the instant case.

Also submitted herewith on Form PTO/SB/08 is an additional listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document in this Form PTO/SB/08 is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not

waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that all listed documents on both the new Form PTO/SB/08 and the prior Form PTO 1449 be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 and Form PTO 1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date January 24, 2003

FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6722
Facsimile: (858) 792-6773

By Barry S. Wilson

Barry S. Wilson
Attorney for Applicant
Registration No. 39,431

ECF1ED 27 17:30

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/062,467
		Filing Date	February 5, 2002
		First Named Inventor	Andrew C. Hiatt
		Group Art Unit	1651
		Examiner Name	
(use as many sheets as necessary)		Attorney Docket Number	068904-0204
Sheet	2	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A10	Allen, et al., "An immunoperoxidase study of epithelial marker antigens in ulcerative colitis with dysplasia and carcinoma." <i>J. Clin. Pathol.</i> , 38:18-29 (1985)	
	A11	Arnold, et al., "Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer." <i>Surgery</i> , 112:624-631 (1992)	
	A12	Ball, et al., "A polarized human endometrial cell line that binds and transports polymeric IgA." <i>In Vitro Cell Biol.</i> , 31:96 (1995)	
	A13	Carayannopoulos, et al., "Localization of the Binding Site for the Monocyte Immunoglobulin (Ig) A-Fc Receptor (CD89) to the Domain Boundary Between Ca2 and Ca3 in Human IgA1." <i>J. Exp. Med.</i> , 183:1579-1586 (1996)	
	A14	Church and Gilbert, "Genomic sequencing." <i>Proc. Natl. Acad. Sci. USA</i> , 81:1991-1995 (1984)	
	A15	Creighton, Thomas E., <i>Proteins – Structures and Molecular Principles</i> , (New York: W.H. Freeman and Co.) pp. 2, 86-87.	
	A16	Folli, et al., "Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice." <i>Cancer Res.</i> , 54:2643-2450 (1994)	
	A17	Hughes, et al., "The amino acid sequence of rabbit J chain in secretory immunoglobulin A." <i>Biochem. J.</i> , 271:641-647 (1990)	
	A18	Janknecht and Nordheim, "Affinity purification of histidine-tagged proteins transiently produced in HeLa cells." <i>Gene</i> , 121:321-324 (1992)	
	A19	Kimball, John W., <i>Introduction to Immunology</i> (New York: Macmillan) pages 264-265, 1983.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/062,467 February 5, 2002 Andrew C. Hiatt 1651 068904-0204
Sheet	3	of	5		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A20	Lemaitre-Coelho, et al., "In vivo experiments involving secretory component in the rat hepatic transfer of polymeric IgA from blood into bile." <i>Immunology</i> , <u>43</u> :261 (1981).		
	A21	Matsuuchi, et al., "Immunoglobulin J chain gene from the mouse." <i>Proc. Natl. Acad. Sci. USA</i> , <u>83</u> :456-460 (1986).		
	A22	Max and Korsmeyer, "Human J chain gene." <i>J. Exp. Med.</i> , <u>161</u> :832-849 (1985).		
	A23	Merrifield, R.B., "Solid phase peptide synthesis: The synthesis of a Tetrapeptide." <i>J. Am. Chem. Soc.</i> , <u>85</u> :2149-2146 (1963).		
	A24	Mikoryak, et al., "J chain in <i>Rana catesbeiana</i> high molecular weight Ig." <i>J. Immunol.</i> , <u>140</u> :4279-4285 (1988).		
	A25	Morton, et al., "Purification and Characterization of Chimeric Human IgA1 and IgA2 Expressed in COS and Chinese Hamster Ovary Cells," <i>The Journal of Immunology</i> , <u>151</u> (9):4743-4752 (1993).		
	A26	Pelegriin, et al., "Antibody-Fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice." <i>Cancer</i> , <u>67</u> :2529-2535 (1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	10/062,467
(use as many sheets as necessary)		Filing Date	February 5, 2002
		First Named Inventor	Andrew C. Hiatt
		Group Art Unit	1651
		Examiner Name	
Sheet	4	of	5
		Attorney Docket Number	068904-0204

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A27	Piskurich, et al., "Molecular cloning of the mouse polymeric Ig receptor: Functional regions of the molecule are conserved among five mammalian species." <i>J. Immunol.</i> , <u>154</u> :1735-1747 (1995)	
	A28	Suemori, et al., "Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family." <i>Proc. Natl. Acad. Sci.</i> , <u>88</u> :11017-11021 (1991).	
	A29	Takahashi, et al., "The joining (J) chain is present in invertebrates that do not express immunoglobulins." <i>Proc. Natl. Acad. Sci. USA</i> , <u>93</u> :1886-1891 (1996).	
	A30	Underdown, et al., "Isolation of human secretory component by affinity chromatography." <i>Immunochemistry</i> , <u>14</u> :111-120 (1977).	
	A31	Verma & Somia, "Gene Therapy – promises, problems, and prospects." <i>Nature</i> , <u>389</u> :239-242 (1997).	
	A32	Wagner, et al., "Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes." <i>Science</i> , <u>270</u> :1797-1800 (1995).	
	A33	Weissleder, et al., "Quantitation of slow drug release from an implantable and degradable gentamicin conjugate by In Vivo magnetic resonance imaging." <i>Antimicrobial Agents and Chemotherapy</i> , <u>39</u> (4):839-845 (1995).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/062,467
				Filing Date	February 5, 2002
				First Named Inventor	Andrew C. Hiatt
				Group Art Unit	1651
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	068904-0204
Sheet	5	of	5		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A34	Wells, J. A., "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> , 29(37):8509-8517 (1990).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.